4 Promising Drug Developments in Psoriatic Arthritis Treatment Market
                     4 Promising Drug Developments 
in Psoriatic Arthritis Treatment 
Market
According to the latest data from the National Psoriasis Foundation, over 8
million people in the United States have psoriasis. In psoriatic arthritis,
the underlying inflammation affects bodily systems like the lungs, heart,
and eyes. One primary goal in treating psoriatic arthritis  or psoriasis is
achieving skin clearance. As per Inkwood Research, the global psoriatic
arthritis  treatment  market growth  is  anticipated  to  progress  at
a CAGR of 7.64% during 2023-2032.
This  blog  discusses  the  four  promising  drug  developments  for
psoriatic arthritis treatment.
1. Sun  Pharma  announces  China  NMPA  Approval
for ILUMETRI
On 30th May  2023, Sun  Pharmaceutical  Industries announced  the
approval  of  a  New  Drug  Application  (NDA)  for tildrakizumab  injection
under ILUMETRI by  the  National  Medical  Products  Administration  of  the
People’s Republic of China.
ILUMETRI is indicated for treating adults with moderate-to-severe plaque
psoriasis  who  are  candidates  for  phototherapy  or  systemic  therapy.
In June 2019, tildrakizumab was out-licensed by a China Medical System
Holdings  Limited  (CMS)  subsidiary  for  commercialization,  regulatory
filings, and development of the product in Greater China.
As per CMS, the Phase III clinical trial results showed a continual increase
in the primary efficacy assessment indicator PASI 75 response over the
treatment  time. Tildrakizumab Injection  has  also  been  approved  in  the
United Kingdom, the United States, Japan, European Union, Hong Kong,
Australia,  Canada,  Switzerland,  etc.,  under  brands
like ILUMETRI and ILUMYA.
2. BIOCAD showcases Netakimab’s efficacy at EULAR 2020
Netakimab is an anti-interleukin 17A antibody approved and humanized
for treating moderate-to-severe plaque psoriasis. The phase III clinical trial
PATERA assessed the Netakimab‘s effects on the symptoms and signs of
psoriatic arthritis, including quality of life, skin manifestation, and disease
activity.
The  trial  included 194 eligible  psoriatic  arthritis  patients  who  received
either a placebo or 120 mg of Netakimab subcutaneously for 24 weeks.
The drug was well-endured and the effects were mild to moderate. No
anti-drug  antibodies  were  detected  and  no  treatment-related  severe
adverse effects.
3. Priovant Therapeutics’ Brepocitinib on a Unique Quest
Brepocitinib is  a  drug  being  tested  for  possible  treatment  for  many
immunocompromising conditions like dermatomyositis,  ulcerative colitis,
and systemic lupus erythematosus. However, Brepocitinib‘s phase II trial
has also exhibited positive outcomes for psoriatic arthritis treatment.
Further, Brepocitinib works  by  hindering  the  inflammation-causing
immune response, which forms the core of psoriatic arthritis. The drug is
unique since it obstructs two enzymes, JAK1 and TYK2, which play a huge
role  in  autoimmune  disease.  Presently, Brepocitinib is  the  only  dual
inhibitor in late-stage development.
Dr. Ruth Ann Vleugels,  a principal investigator for the Priovant study
 of    Brepocitinib    in dermatomyositis , says, “Years of experience using JAK
inhibitors  in  patients  with  dermatomyositis  has  shown  us  that  these
agents can profoundly benefit patients with uncontrolled disease. Given
the  devastating  manifestations  of  dermatomyositis  and  its  substantial
impact  on  quality  of  life,  the  benefits  of  treatment  with  JAK  inhibitors
outweigh the potential risks in the vast majority of patients in our clinic.”
(Source)
4. AbbVie  gets  FDA  approval  for SKYRIZI®  (risankizumab-
rzaa)
On 21st January  2022, AbbVie announced  the  U.S.  Food  and  Drug
Administration  (FDA)  ‘s  approval  of  SKYRIZI  ®  for  treating  adults  with
active psoriatic arthritis. The approval is supplemented by data from two
pivotal  studies,  KEEPsAKE-1  and  KEEPsAKE-2.  These  studies
assessed SKYRIZI®’s  safety  and efficacy in  adults  with  active  psoriatic
arthritis.
SKYRIZI dictates  a  dosing  procedure  for  psoriatic  arthritis,  which  is  in
tandem  with  the  existing  procedure  for  moderate-to-severe  plaque
psoriasis patients. It displayed considerable improvements across many
manifestations of psoriatic arthritis, including painful, tender, and swollen
joints.
Says Alan J. Kivitz, M.D, clinical trial investigator of KEEPsAKE, “In the
pivotal  KEEPsAKE  trials,  SKYRIZI  demonstrated  improvements  across  a
number of psoriatic arthritis symptoms, including joint pain, enthesitis and
dactylitis.  This  approval  provides  both  dermatologists  and
rheumatologists  with  an  option  that  helps  improve  skin  and  joint
symptoms in patients with active psoriatic arthritis, alongside a quarterly
dosing schedule that may fit their patients’ lifestyle.” (Source)
Such  product  developments  enhance  the  global  psoriatic  arthritis
treatment market growth prospects.
FAQs:
1. Which is the largest revenue-generating region in the global
psoriatic arthritis treatment market?
A: North America is the largest revenue-generating region in the 
global psoriatic arthritis treatment market.
2. Which is the prominent drug type in the global psoriatic 
arthritis treatment market?
A: Disease-modifying antirheumatic drugs (DMARDs) are the 
prominent drug type in the global psoriatic arthritis treatment 
market.